Table 1. Random effects estimates with 95% confidence and prediction intervals from 27 meta-analyses of type 2 diabetes mellitus and incidence of cancer or mortality.
| Cancer origins | No. of cases | Random effects (95% CI) |
|---|---|---|
| Total cancer incidence | 38,010 | 1.10 (1.04–1.17) |
| Total cancer mortality | 11,386 | 1.16 (1.04–1.30) |
| Prostate cancer incidence | 135,970 | 0.91 (0.82–1.01) |
| Thyroid cancer incidence | 1,230 | 1.16 (0.97–1.39) |
| Lung cancer incidence | 207,454 | 1.03 (0.94–1.13) |
| Gastric cancer incidence | 15,970 | 1.09 (0.98–1.22) |
| Gastric cancer mortality | 2,447 | 1.29 (1.04–1.59) |
| Colorectal cancer incidence | 61,690 | 1.27 (1.21–1.34) |
| Colorectal cancer mortality | 4,394 | 1.20 (1.03–1.40) |
| Hepatocellular carcinoma incidence | 33,765 | 2.31 (1.87–2.84) |
| Hepatocellular carcinoma mortality | 292 | 2.43 (1.67–3.55) |
| Breast cancer incidence | 30,859 | 1.20 (1.12–1.28) |
| Breast cancer mortality | 4,442 | 1.24 (0.95–1.62) |
| Endometrial cancer incidence | 8,174 | 1.97 (1.71–2.27) |
| Endometrial cancer mortality | 103 | 1.23 (0.78–1.93) |
| Ovarian cancer incidence | 7,651 | 1.17 (1.02–1.34) |
| Kidney cancer incidence | 12,980 | 1.38 (1.10–1.72) |
| Kidney cancer mortality | 2,646 | 1.16 (1.01–1.33) |
| Esophageal cancer incidence | 3,001 | 1.30 (1.12–1.50) |
| Bladder cancer incidence | 50,676 | 1.35 (1.17–1.56) |
| Gallbladder cancer incidence | 1,821 | 1.52 (1.26–1.84) |
| Extrahepatic cholangiocarcinoma incidence | 2,431 | 1.63 (1.29–2.05) |
| Pancreatic cancer incidence | 52,445 | 1.95 (1.66–2.28) |
| Intrahepatic cholangiocarcinoma incidence | 3,152 | 1.97 (1.57–2.46) |
| Multiple myeloma incidence | 3,051 | 1.27 (0.98–1.64) |
| Non-Hodgkin's lymphoma incidence | 12,353 | 1.27 (1.09–1.48) |
| Leukemia incidence | 4,156 | 1.28 (1.05–1.57) |
Modified from Tsilidis et al. [10].
CI, confidence interval.